R&D & QUALITY
How to read global pharma's public R&D and quality material
Public material from Roche, Pfizer, GSK, Novartis, Lilly, Johnson & Johnson, Takeda and Boehringer Ingelheim can illuminate methods, but it does not itself prove a product's effectiveness, quality or marketing status.
Read the complete chain
A medicine does not move directly from a promising molecule to a finished product. Public research material commonly describes disease biology and target hypotheses, discovery and candidate selection, experimental models and non-clinical work to reduce uncertainty, controlled clinical research, regulatory submissions, process development, supply and post-marketing monitoring. Each stage answers a different question; early experiments, company news or pipeline pages do not replace an approved label.
Discovery tools guide; experiments decide
Roche describes human model systems, computation and experiments together as ways to make early models more relevant to human biology. Johnson & Johnson describes combining screening platforms, AI tools and different therapeutic modalities. Computation, automation and high-throughput screening can broaden hypotheses and improve prioritisation, but a candidate still needs reproducibility, developability, safety and progressively stronger evidence. A hit or a research video is not evidence that a product is effective, high quality or authorised.
From target to clinic is not a straight line
GSK, Novartis and Lilly describe disease mechanisms, target evidence, translational research and clinical development as connected but different stages. The essential distinction is between scientific rationale and clinical benefit: rationale can explain why a question is worth studying, while benefit needs suitable participants, endpoints, controls and statistical analysis. Novartis distinguishes early biomedical research from large clinical development; Pfizer notes that research can continue before and after approval.
Different modalities bring different questions
Small molecules, antibodies, RNA, radioligands, cell and gene therapies, and plasma-derived therapies differ in discovery, analysis, manufacture and supply. Public material from Novartis, Johnson & Johnson and Takeda describes multi-modality research platforms. Readers should therefore not infer dosage form, route, storage, handling, interchangeability or price from a shared non-proprietary name or disease area. Check the particular product, market and current label.
Manufacturing and quality are controlled systems, not a promotional image
Research success does not automatically mean every batch meets its standards. Manufacturing connects an established process, facilities, starting materials and excipients, analytical methods, deviation handling, change control and batch records. Lilly's public material describes the role of manufacture and quality; regulatory current good manufacturing practice requirements provide a common language for checking a product quality system. Public information can explain the concepts, but batch status, authenticity and lawful supply depend on the actual label, traceability records, authorisation holder and regulator information.
Use company material without letting it replace a decision
Company pages can answer how a research team describes its methods, platform or programme. Regulatory labels and databases can answer the current approval and safety information for a particular product in a particular market. Peer-reviewed papers can answer what methods, results and limitations apply to a specific research question. OriginDrug keeps these evidence layers distinct: company material is for method reading, primary regulatory records are for product checking, and treatment or purchasing decisions still need a target-market clinician, pharmacist and lawful service provider.
Four questions for a research or manufacturing video
Who made the video, and what setting does it show? Does it show early discovery, clinical research or commercial manufacturing? Does it clearly correspond to an approved product and market? Can its claims be checked against a regulatory record or original paper? This approach allows a reader to learn from research and production footage without treating visual presentation as a conclusion about the quality, origin or effect of a particular medicine.
PRIMARY REFERENCE
Source evidence
Each entry identifies its market, document type, access mode and most recent review date. Public access does not make a document applicable to every market or person. Read the review method.
- Roche: Research and development ↗reviewed 2026-08-20
- Pfizer: Research and Development ↗reviewed 2026-08-20
- GSK: Innovation ↗reviewed 2026-08-20
- Novartis: Research and development ↗reviewed 2026-08-20
- Eli Lilly: Research & Development ↗reviewed 2026-08-20
- Johnson & Johnson: Discovery, product development & supply ↗reviewed 2026-08-20
- Takeda: Research and development ↗reviewed 2026-08-20
- Boehringer Ingelheim: Partnering interests ↗reviewed 2026-08-20
- FDA: Facts About Current Good Manufacturing Practice (cGMP) ↗reviewed 2026-08-20